KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Leases (2016 - 2025)

Regeneron Pharmaceuticals has reported Leases over the past 12 years, most recently at $576.7 million for Q4 2025.

  • Quarterly results put Leases at $576.7 million for Q4 2025, down 2.45% from a year ago — trailing twelve months through Dec 2025 was $576.7 million (down 2.45% YoY), and the annual figure for FY2025 was $576.7 million, down 2.45%.
  • Leases for Q4 2025 was $576.7 million at Regeneron Pharmaceuticals, down from $591.2 million in the prior quarter.
  • Over the last five years, Leases for REGN hit a ceiling of $631.3 million in Q4 2021 and a floor of $576.7 million in Q4 2025.
  • Median Leases over the past 5 years was $605.7 million (2023), compared with a mean of $605.0 million.
  • Biggest five-year swings in Leases: fell 1.74% in 2022 and later decreased 2.45% in 2025.
  • Regeneron Pharmaceuticals' Leases stood at $631.3 million in 2021, then dropped by 1.74% to $620.3 million in 2022, then dropped by 2.35% to $605.7 million in 2023, then decreased by 2.39% to $591.2 million in 2024, then decreased by 2.45% to $576.7 million in 2025.
  • The last three reported values for Leases were $576.7 million (Q4 2025), $591.2 million (Q4 2024), and $605.7 million (Q4 2023) per Business Quant data.